May 30th 2017EP. 1: Selecting Therapy to Meet Individual Needs
May 30th 2017EP. 2: When to Start Insulin? Lack of Consensus on Targets
May 30th 2017EP. 3: Comparing New Insulins to Older Formulations
May 30th 2017EP. 4: Understanding Factors Behind Insulin Costs
May 30th 2017EP. 5: Formulary Decisions and Clinical Practice
May 30th 2017EP. 6: Glycemic Control Is the Bottom Line
May 30th 2017EP. 7: The Advantages of Insulin, GLP-1 Combinations
May 30th 2017EP. 8: Adherence Matters When Weighing a Single Injection
May 30th 2017EP. 9: Juggling Multiple Factors When Selecting Therapy
May 30th 2017EP. 10: Formulary Management: Antidiabetes Medications
May 30th 2017EP. 11: Barriers to Traditional Insulin Therapy
May 30th 2017EP. 12: Evidence With Ultra–Long Acting Insulins
May 30th 2017EP. 13: Appropriate Access: Payer Perspective on Newer Insulins
May 30th 2017EP. 14: Cardiovascular Considerations in Antidiabetic Therapies
May 30th 2017EP. 15: Formulary Decisions and GLP-1/Insulin Combinations
May 30th 2017EP. 16: Role of GLP-1/Insulin Combinations
May 30th 2017EP. 17: Barriers to Insulin Therapy in Type 2 Diabetes
May 30th 2017EP. 18: Practical Decisions in Type 2 Diabetes
May 30th 2017EP. 19: Deciding Among Insulin Therapies for Type 2 Diabetes
May 30th 2017EP. 20: Formulary Access to Insulins in Type 2 Diabetes
May 30th 2017EP. 21: Clinical Evidence of Insulin Degludec in Type 2 Diabetes
May 30th 2017EP. 22: Hypoglycemia: An Unrecognized Complication in Diabetes
May 30th 2017EP. 23: Access to Therapeutic Combinations in Type 2 Diabetes
May 30th 2017EP. 24: Impact of Cardiovascular Data in Type 2 Diabetes
May 30th 2017EP. 25: Understanding the DUAL VII Findings in Type 2 Diabetes
May 30th 2017EP. 26: The Importance of Real-World Data in Type 2 Diabetes
